Prognostic Factors in First-Line Chemotherapy Treated Metastatic Gastric Cancer Patients: A Retrospective Study

Ali Inal1*, M Ali Kaplan1, Mehmet Kuçukoner1, Zuhat Urakcı1, Mehmet Guven2, Necip Nas2, Muharrem Yunce3, Abdurrahman Işıkdogan1

Abstract

Background: The majority of patients with gastric cancer in developing countries present with advanced disease. Systemic chemotherapy therefore has limited impact on overall survival. Patients eligible for chemotherapy should be selected carefully. The aim of this study was to analyze prognostic factors for survival in advanced gastric cancer patients undergoing first-line palliative chemotherapy.

Methods: We retrospectively reviewed 107 locally advanced or metastatic gastric cancer patients who were treated with docetaxel and cisplatin plus fluorouracil (DCF) as first-line treatment between June 2007 and August 2011. Twenty-eight potential prognostic variables were chosen for univariate and multivariate analyses.

Results: Among the 28 variables of univariate analysis, nine variables were identified to have prognostic significance: performance status, histology, location of primary tumor, lung metastasis, peritoneum metastasis, ascites, hemoglobin, albumin, weight loss and bone metastasis. Multivariate analysis by Cox proportional hazard model, including nine prognostic significance factors evident in univariate analysis, revealed weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level to be independent variables.

Conclusion: Performance status, weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level were identified as important prognostic factors in advanced gastric cancer patients. These findings may facilitate pretreatment prediction of survival and can be used for selecting patients for treatment.

Keywords: Gastric cancer - first-line chemotherapy - prognostic factors

Asian Pacific J Cancer Prev, 13, 3869-3872

Introduction

Despite the reduced incidence, gastric cancer is the second most common among cancer-related deaths in the world. In two-thirds of patients with gastric cancer are diagnosed with metastatic disease (Kamangar et al., 2006; Jemal et al., 2011). Without effective treatment, the median survival for metastatic disease is 3 to 5, however it may be extended 8-12 months with the platinum and taxane-containing regimens (Van Cutsem et al., 2006; Roth et al., 2007). Randomized trials have shown that systemic chemotherapy resulted in a significant survival benefits when compared with best supportive care (Murad et al., 1993; Pyrhom et al., 1995; Glimelius et al., 1997). The meta-analysis by Wagner et al. suggests that the combination chemotherapy response rates over monotherapy alone in patients with advanced gastric cancer (Wagner et al., 2006). In the Tax 325 study, two regimens were compared; 75 mg/m2 docetaxel and cisplatin on day 1 and 750 mg/m2 5-Fluorouracil continuous infusion per day on days 1-5, every 3 weeks (DCF) versus cisplatin 100 mg/m2 on day 1 and 1000 mg/m2 5-Fluorouracil continuous infusion per day on days 1–5, every 4 weeks (CF). The DCF arm response rates (37 vs 25%) and overall survival (OS) higher than CF arm, while the toxicities of grade 3 to 4 was higher in the DCF arm (Van Cutsem et al., 2006).

Very different prognostic factors in several studies have been identified for survival in patients with advanced gastric cancer (Tsujitani et al., 2001; Chau et al., 2004; Yoshida et al., 2004; Kim et al., 2008; Roshanaei et al., 2011; Maroufizadeh., 2012). Systemic chemotherapy for patients with gastric cancer has limited impact on OS due to not only a low response rates, but also severe side effects. Determining the prognostic factors of survival for metastatic gastric cancer patients with first-line chemotherapy treated patients can help physicians in the decision-making process for individual patients.

We performed a retrospective analysis of prognostic factors in the metastatic gastric cancer patients treated with first-line DCF chemotherapy.

Materials and Methods

Patient Population

We retrospectively reviewed 107 locally advanced or
metastatic gastric cancer patients who were treated DCF as first-line treatment between June 2007 and August 2011. All had advanced gastric cancer. Patients who had received prior treatment were excluded.

**Treatment and Assessment**

The DCF protocol included 50-75 mg/m² docetaxel and cisplatin on day 1 and 500-750 mg/m²/day 5-FU infusion for 5 days, repeated every 3 weeks. Imaging studies were documented by computed tomography at baseline and every three cycles for patients.

The responses to chemotherapy were measured according to Response Evaluation Criteria in Solid Tumors (RECIST).

**Factors Analyzed**

Twenty-eight clinical variables [age, gender, prior gastrectomy, performance status, location of primary tumor, stage, grade, histology, diabetes mellitus, hypertension, weight loss, dose reduction, second-line chemotherapy, liver metastasis, lung metastasis, bone metastasis, peritoneum metastasis, ascites, hemoglobin (Hb), WBC count, platelet (PLT) count, serum albumin (alb), serum calcium, serum alkaline phosphatase (ALP), serum lactic dehydrogenase (LDH), serum total bilirubin, serum carcinoembryonic antigen (CEA) level and serum carbohydrate antigen 19-9 (CA19-9) level] were chosen on the basis of previously published clinical trials.

**Statistical Analysis**

All of the analyses were performed using the SPSS statistical software program package (SPSS version 11.0 for windows). The differences of the clinical characteristics between the two groups were analyzed by chi-square test and student t test. Overall survival (OS) was calculated with the log-rank test. The Kaplan–Meier method was used survival curves. The Cox proportional hazards regression model was used to determine statistical significant variables related to survival. Differences were assumed to be significant when the P value was less than 0.05.

**Results**

**Patient Characteristics**

Between June 2007 to August 2011, 107 untreated patients with locally advanced and metastatic gastric cancer were enrolled in this study. The median age of patients was 52 years (range 23-76) with 69 males and 38 females. Ninety-two patients (86%) were diagnosed as having metastatic gastric cancer and 15 patients (14%) had locally advanced gastric cancer. 28 patients (26.2%) received second-line chemotherapy. The median OS was 9.0 months. The patient’s baseline characteristics are listed in Table 1.

**Prognostic Factor Analysis**

The results of univariate analysis are summarized in Table 2. Among the twenty-eight variables of univariate analysis, eight variables were identified to have prognostic significance: Performance status (P=0.003), histology (P=0.02), location of primary tumor (P=0.003), lung metastasis (P=0.02), peritoneum metastasis (P<0.001), ascites (P<0.001), hemoglobin (P=0.03), albumin (P=0.03). In addition, weight loss and bone metastasis showed borderline significance (p=0.06).

Multivariate analysis included the nine prognostic significance factors observed to be significant on univariate analysis. The results of multivariate analysis are shown in Table 3. Multivariate analysis by Cox proportional hazard model showed that performance status was considered independent prognostic factors for survival, as were weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level.

**Table 1. General Characteristics of the Patients**

| Characteristic | No. of patients (%) |
|---------------|---------------------|
| Sex: Male     | 69 (64.50)          |
| Female        | 38 (35.53)          |
| Age, median (range) | 52 (23-76) |
| Age, <65      | 90 (84.1)           |
| ≥65           | 17 (15.9)           |
| Performance status: 0-1 | 77 (72.0) |
| 2-3           | 28 (26.2)           |
| Unknown       | 2 (1.9)             |
| Stage: Locally advanced | 15 (14.0) |
| Metastatic    | 92 (86.0)           |
| Histology: Adenocarcinoma | 72 (68.3) |
| Mucinous adenocarcinoma | 31 (29.0) |
| Signet ring cell carcinoma | 4 (3.7) |
| Grade: Well   | 6 (5.6)             |
| Moderate      | 12 (11.2)           |
| Poor          | 17 (15.9)           |
| No data       | 77 (72.0)           |
| Location of primary tumor: Gastroesophageal junction | 15 (14.0) |
| Fundus        | 3 (2.8)             |
| Body          | 21 (19.6)           |
| Antrum        | 35 (32.7)           |
| Total         | 8 (7.5)             |
| Unknown       | 25 (23.4)           |
| Dose reduction| 27 (25.2)           |
| Second-line chemotherapy | 28 (26.2) |
| Diabetes Mellitus | 6 (6.5) |
| Weight loss   | 58 (56.3)           |
| Hypertansiyon | 9 (8.4)             |
| Metastatic sites: Liver | 47 (43.9) |
| Lung          | 8 (7.5)             |
| Bone          | 7 (6.5)             |
| Peritoneum    | 39 (36.4)           |
| Ascites       | 28 (26.2)           |
| Prior gastrectomy | 48 (44.9) |

Baseline laboratory parameters, median:

| Hemoglobin, g/l | 10.6 |
| WBC            | 8500 |
| PLT            | 347  |
| Albumin, g/dl  | 3    |
| Alkaline phosphatase, U/l | 90 |
| LDH, U/l       | 238  |
| Total Bilirubin, mg/dl | 0.5 |
| Calcium, mg/dl | 8.4  |
| CEA, ng/mL     | 5    |
Table 2. Univariate Analysis of Survival Time by Categorical Variable (Degrees of freedom=1)

| Variable                          | Log-rank test value | p   |
|----------------------------------|---------------------|-----|
| Age                              | 0.4                 | 0.5 |
| Sex                              | 0.001               | 0.9 |
| Stage                            | 1.6                 | 0.2 |
| Grade                            | 4.3                 | 0.2 |
| Performance status               | 8.7                 | 0.03|
| Histology                        | 7.2                 | 0.02|
| Location of primary tumor        | 3.4                 | 0.003|
| Dose reduction                   | 0.2                 | 0.6 |
| Second-line chemotherapy         | 3.1                 | 0.08|
| Weight loss                      | 3.4                 | 0.06|
| Diabetes Mellitus                | 0.1                 | 0.7 |
| Hypertansiyon                    | 0.02                | 0.9 |
| Prior gastrectomy                | 0.5                 | 0.4 |
| Liver metastasis                 | 0.1                 | 0.8 |
| Lung metastasis                  | 5.0                 | 0.02|
| Bone metastasis                  | 3.3                 | 0.06|
| Peritoneum metastasis            | 17.7                | <0.001|
| Ascites                          | 13.4                | <0.001|
| Hemoglobin                       | 4.4                 | 0.03|
| Alb                              | 4.7                 | 0.03|
| WBC                              | 2.0                 | 0.1 |
| PLT                              | 0.4                 | 0.4 |
| Alkaline phosphatase             | 2.2                 | 0.1 |
| LDH                              | 0.1                 | 0.6 |
| Total Bilirubin                  | 0.2                 | 0.6 |
| Calcium                          | 0.02                | 0.8 |
| CEA                              | 0.1                 | 0.7 |
| CA19-9                           | 0.5                 | 0.8 |

Table 3. Multivariate Analysis of Prognostic Factors

| Parameter                          | OR     | 95% CI      | p value |
|-----------------------------------|--------|-------------|---------|
| Performance status                | 0.06   | 0.15-0.24   | <0.001  |
| Weight loss                       | 3.06   | 1.27-7.36   | 0.012   |
| Histology                         | 0.21   | 0.07-0.60   | 0.004   |
| Peritoneum metastasis             | 0.33   | 0.09-1.23   | 0.06    |
| Ascites                           | 0.13   | 0.03-0.49   | 0.03    |
| Hemoglobin                        | 4.66   | 1.61-13.4   | 0.004   |

Discussion

Systemic chemotherapy for patients with gastric cancer has limited impact on OS due to not only a low response rates, but also severe side effects. Patients eligible for chemotherapy should be selected carefully. This retrospective study analyzed prognostic factors for survival in advanced gastric cancer patients who were undergoing first-line palliative DCF chemotherapy.

On univariate analysis, nine of twenty-eight potential factors were identified as significant prognostic factors for survival. However, only six independent significant prognostic factors were found on multivariate analysis: performance status, weight loss, histology, peritoneum metastasis, ascites and serum hemoglobin level.

A poor performance status is usually accepted a negative prognostic factor for all cancer patients (Chau et al., 2004; Mitry et al., 2004; Hoang et al., 2005; Krishnan et al., 2006; Lee et al., 2007). The importance of this marker was also confirmed in advanced gastric cancer patients (Yoshida et al., 2004; Lee et al., 2007; Kim et al., 2008). Similarly performance status found that the prognostic importance for survival in our study.

The weight loss is usually associated with gastro-esophageal malignancy. Increased weight loss may represent a more aggressive tumour biological behaviour and increased tumour burden. Weight loss was found to be an independent prognostic factor of survival (Andreyev et al., 1998; Sougioutzis et al., 2010), while Kanagavel et al. (2010) no observed significant effect for overall survival. In our study, weight loss is found to be independent risk factor for survival.

The prognostic significance of peritoneal metastases and ascites with advanced gastric cancer was investigated in few clinical studies. It has been shown significantly associated with in some clinical studies (Kim et al., 2008; Chau et al., 2004; Sadeghi et al., 2005), whereas Kanagavel et al.(2010) had showed that the low hemoglobin level had no significant effect for overall survival.

In our retrospective study, peritoneum metastasis and ascites were found to be an independent prognostic factor for survival.

Anemia is common among advanced gastric cancer patients. Anemia may be caused by many factors. These include a result of bleeding, chemotherapy-induced myelosuppression, marrow infiltration by tumor, hemolysis, nutritional deficiency or cytokine-mediated anemia of chronic disease. The previously by many authors (Chau et al., 2004; Park et al., 2006; Kim et al., 2008; Kanagavel et al., 2010) had showed that the low hemoglobin level in patients with advanced gastric cancer is correlated independently with poor prognosis, while in some studies (Lee et al., 2007; Kim et al., 2008), the low hemoglobin level had no significant effect for overall survival. In our analysis, anemia was found to be an independent prognostic factor on survival in patients receiving first-line therapy.

The histological patterns of gastric cancer also vary from country to country. These may depend on the prevalent socioeconomic conditions, genetic and environmental factors. The prognostic significance of histological subtype with advanced gastric cancer patients was investigated in few clinical trials (Kanagavel et al., 2010). Kanagavel et al. had no prognostic importance for survival. Unlike earlier studies, our study found that histological subtype is an independent risk factor for survival.

The present study has some limitations which need to be taken into account. Firstly, its retrospective study. Secondly, we did not evaluate molecular characteristics of the tumor. Thirdly, there was the small number of patients.

In conclusion, age, weight loss, liver metastasis, serum CEA level and serum CA19-9 level were identified as important prognostic factors in advanced gastric cancer patients who were undergoing first-line palliative gemcitabine alone or gemcitabine plus cisplatin. These findings may also facilitate pretreatment prediction of survival and can be used for selecting patients for treatment. However, before final conclusion can be drawn, larger prospective and clinical trials need to be conducted for confirmation.
References

Andreyev HJ, Norman AR, Oates J, Cunningham D (1998). Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? *Eur J Cancer, 34*, 503-9.

Chau I, Norman AR, Cunningham D, et al (2004). Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer—pooled analysis from three multicenter, randomized, controlled trials using individual patient data. *J Clin Oncol, 15*, 2395-403.

Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. *CA Cancer J Clin, 61*, 69-90.

Glimelius B, Ekstrom K, Hoffman K, et al (1997). Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. *Ann Oncol, 8*, 163-8.

Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH (2005). Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. *J Clin Oncol, 23*, 175-83.

Kamangar F, Dores GM, Anderson WF (2006). Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *JCO, 24*, 2137-50.

Kanagavel D, Pokataev IA, Fedyanin MY, et al (2010). A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. *Ann Oncol, 21*, 1779-85.

Kim JG, Ryoo BY, Park YH, et al (2008). Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. *Cancer Chemother Pharmacol, 61*, 301-7.

Krishnan S, Rana V, Janjan NA, et al (2006). Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. *Cancer, 107*, 2589-96.

Lee J, Lim T, Uhm JE, et al (2007). Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. *Ann Oncol, 18*, 886-91.

Maroufizadeh S, Maroufizadeh S, Hajizadeh E, Baghestani AR, Fatemi SR (2011). Multivariate analysis of prognostic factors in gastric cancer patients using additive hazards regression models. *Asian Pac J Cancer Prev, 12*, 1697-702.

Mitry E, Douillard JY, van Cutsem E, et al (2004). Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. *Ann Oncol, 15*, 1013-7.

Murad AM, Santiago FF, Petroianu A, et al (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. *Cancer, 72*, 37-41.

Park SH, Lee J, Lee SH, et al (2006). Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. *Cancer Chemother Pharmacol, 57*, 91-6.

Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995). Randomized comparison of fluorouracil epirubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. *Br J Cancer, 71*, 587-91.

Roshanaei G, Ghannad MS, Jafarabadi MA, Faradmal J, Sadighi S (2011). Prognostic impact of risk factors in patients with gastric cancer in Iran. *Asian Pac J Cancer Prev, 12*, 3005-8.

Roth AD, Fazio N, Stupp R, et al (2006). Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. *J Clin Oncol, 25*, 3217-23.

Roshanaei G, Ghannad MS, Jafarabadi MA, Faradmal J, Sadighi S (2011). Prognostic impact of risk factors in patients with gastric cancer in Iran. *Asian Pac J Cancer Prev, 12*, 3005-8.

Sadeghi B, Arvieux C, Glehen O, et al (2000). Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE I multicentric prospective study. *Cancer, 88*, 358-63.

Sougioulizis S, Syrios J, Xynos ID, et al (2010). A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. *Ann Oncol, 21*, 1779-85.

Tsujitani S, Oka S, Suzuki K, et al (2001). Prognostic factors in patients with advanced gastric cancer treated by noncurative resection: a multivariate analysis. *Hepatogastroenterology, 48*, 1504-8.

Van Cutsem E, Moiseyenko VM, Tjulandin SA, et al (2006). V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. *J Clin Oncol, 24*, 4991-7.

Wagner AD, Grothe W, Haering J, et al (2006). Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *J Clin Oncol, 24*, 2903-9.

Yoshida M, Ohtsu A, Boku N, et al (2004). Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. *Jpn J Clin Oncol, 34*, 654-9.